A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of limiting treatment time with acalabrutinib and
obinutuzumab in people who have chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL). The researchers want to find out whether stopping the study drugs when the
cancer responds to the treatment, followed by a period of observation in which no treatment
is given, is better than, the same as, or worse than the usual approach. A usual treatment
for CLL and SLL is to give the study drugs continuously until the cancer progresses, even if
the disease is in remission. But when people receive these drugs for long periods of time,
they can have serious side effects and their cancer can become resistant to treatment.